See Recent Shionogi-Sponsored Congress Presentations
Congresses
As part of our commitment to addressing unmet medical needs, Shionogi continues to investigate approved products and pipeline compounds. Shionogi presents its research at major congress events globally.
The content contained herein is for your information only. No reproduction, alteration, or distribution of this information is permitted. Information about investigational compounds or investigational uses of products does not imply FDA approval of these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the investigational compounds or investigational uses will receive FDA approval. Shionogi does not recommend or suggest use of its products in a manner inconsistent with FDA-approved labeling.
Select a congress event or filter to view available congress presentations.
You Are Viewing Presentations
Activity of cefiderocol and comparator agents against carbapenem-resistant Enterobacterales, including molecularly characterized isolates recovered from United States hospitals in 2020–2024
Activity of cefiderocol and comparator agents against carbapenem-resistant Enterobacterales, including molecularly characterized isolates recovered from United States hospitals in 2020–2024
Activity of cefiderocol and comparator agents against metallo-β-lactamase carrying Acinetobacter baumannii-calcoaceticus complex isolates collected in the SENTRY antimicrobial surveillance program
Activity of cefiderocol and comparator agents against metallo-β-lactamase carrying Acinetobacter baumannii-calcoaceticus complex isolates collected in the SENTRY antimicrobial surveillance program
Analyzing trends of cefiderocol susceptibility across five years of the SENTRY surveillance program
Analyzing trends of cefiderocol susceptibility across five years of the SENTRY surveillance program
Cefiderocol remains active against US clinical isolates of Stenotrophomonas maltophilia non-susceptible to comparator agents: results from the SENTRY antimicrobial surveillance program (2020–2024)
Cefiderocol remains active against US clinical isolates of Stenotrophomonas maltophilia non-susceptible to comparator agents: results from the SENTRY antimicrobial surveillance program (2020–2024)
Clearance of infectious virus in COVID-19 patients treated with ensitrelvir across vaccination status, age, and risk subgroups: exploratory analyses from the SCORPIO-HR study
Clearance of infectious virus in COVID-19 patients treated with ensitrelvir across vaccination status, age, and risk subgroups: exploratory analyses from the SCORPIO-HR study
Clinical outcomes of cefiderocol for treatment of bloodstream infections caused by gram-negative bacteria: subgroup analysis of the PROVE study
Clinical outcomes of cefiderocol for treatment of bloodstream infections caused by gram-negative bacteria: subgroup analysis of the PROVE study